Over a 9 year period at a single institution, random bladder biopsies were obtained at the time of initial resection in 229 patients. It is not made clear if it was 229 consecutive patients or selected patients – patient selection was not indicated. Random bladder biopsies were taken from seven locations: bladder trigone, posterior wall, dome, right lateral, left lateral, anterior wall and bladder neck. It is unclear if this was done prior to or after resection of the primary lesions. In terms of outcomes, they evaluated the relationship between the random bladder biopsies, the characteristics of the primary tumor/lesion, urine cytology, and patient predisposing factors.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
What this study fails to assess is the added benefit of RBB over traditional TURBT? Did the biopsies find anything that would have changed management? Are there any subsets for whom we should consider adding RBB to white light cystoscopy?
The NMIBC guidelines section of the SIU-ICUD Session on Bladder Cancer highlights the indications for RBB. This was presented by Dr. Kassouf earlier in this conference. Summary available on the UroToday website
Presented by: Koji Iinuma
Written by: Thenappan Chandrasekar, MD, Clinical Fellow, University of Toronto, twitter: @tchandra_uromd, at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal